Disc Medicine disclosed layoffs affecting roughly 30 employees after the FDA declined approval of the company’s experimental drug, according to a public filing. Management said the reductions followed the regulatory setback and were intended to reduce operating expenses while the company evaluates next steps. The job cuts underscore the sensitivity of small biotech balance sheets to single regulatory decisions. Disc Medicine notified stakeholders that the timing of the filing was intentionally scheduled to minimize market disruption. Industry observers noted the episode illustrates how pivotal FDA rulings can be to company viability and hiring decisions, especially for firms awaiting a first approval.